Yes, Caplyta (lumateperone) is an antipsychotic. Specifically, it’s classified as a second-generation (atypical) antipsychotic, meaning it works differently from older antipsychotic medications developed in the mid-20th century. It comes as a 42 mg capsule taken once daily and is FDA-approved for two conditions: schizophrenia in adults and depressive episodes associated with bipolar I and bipolar II disorder.
What Caplyta Is Approved to Treat
Caplyta first received FDA approval for schizophrenia in adults. Then in 2021, the FDA expanded its approval to include bipolar depression, both as a standalone treatment and as an add-on to mood stabilizers like lithium or valproate. That expansion was notable because it made Caplyta one of only four treatments approved by the FDA for both bipolar I and bipolar II depression. Many medications in this space are approved for one or the other, not both.
It’s worth noting that Caplyta is not approved for treating mania, the “up” episodes in bipolar disorder. Its role in bipolar disorder is specifically for the depressive episodes, the prolonged lows that many people with bipolar disorder find hardest to manage.
How It Differs From Older Antipsychotics
The term “antipsychotic” can be misleading, especially for people taking Caplyta for bipolar depression rather than schizophrenia. Older antipsychotics (first-generation drugs like haloperidol) primarily worked by strongly blocking dopamine receptors in the brain. That approach was effective for psychotic symptoms but came with significant movement-related side effects like stiffness, tremors, and involuntary muscle contractions.
Caplyta takes a different approach. It interacts with multiple receptor systems in the brain simultaneously, including dopamine, serotonin, and glutamate pathways. Rather than heavily blocking dopamine the way older drugs do, it modulates these systems more gently. This broader, lighter-touch mechanism is what earns it the “atypical” label and is part of why its side effect profile looks different from both first-generation antipsychotics and some other second-generation options.
Common Side Effects
The side effects people experience with Caplyta depend somewhat on what they’re taking it for. In schizophrenia trials, the most frequently reported side effects were sleepiness, nausea or vomiting, fatigue, decreased appetite, dry mouth, and dizziness.
For bipolar depression, the list overlaps but includes a few additional effects: headache, diarrhea, abdominal pain, upper respiratory infections (like the common cold), and blurry vision. Some people also experienced increased prolactin levels, a hormonal change that can affect menstrual cycles and breast tissue. Both blurry vision and prolactin changes were specifically noted when Caplyta was taken alongside lithium or valproate rather than on its own.
One area where Caplyta stands out among antipsychotics is weight gain. Many second-generation antipsychotics are associated with meaningful weight increases and metabolic changes like rising blood sugar or cholesterol. In Caplyta’s clinical trials, the proportion of people who gained weight was similar to those taking a placebo. For people who have struggled with weight-related side effects on other antipsychotics, this is often a key part of the conversation with their prescriber.
How It’s Taken
Caplyta is taken as a single 42 mg capsule once a day. You can take it with or without food, and there’s no need for dose titration, the gradual ramp-up period that many psychiatric medications require. You start at the full dose from day one. There is only one available dose strength, so there’s no adjustment based on body weight or symptom severity.
Why an Antipsychotic for Depression
If you’re researching Caplyta because it was prescribed for bipolar depression, you might feel uneasy seeing the word “antipsychotic” on the label. This is a common reaction. The name reflects the drug class these medications were originally developed for, not necessarily why your doctor prescribed it. Several atypical antipsychotics are now routinely used to treat mood disorders, including bipolar depression and treatment-resistant major depression, because they affect serotonin and other neurotransmitter systems beyond just dopamine.
Caplyta’s approval for bipolar depression was based on clinical trials showing it reduced depressive symptoms significantly more than placebo in people with both bipolar I and bipolar II disorder. Its relatively favorable side effect profile, particularly around weight and metabolic effects, has made it a commonly considered option when other treatments haven’t worked well or have caused intolerable side effects.